A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany

Christina Bahrs; Miriam Kesselmeier; Martin Kolditz; Santiago Ewig; Gernot Rohde; Grit Barten-Neiner; Jan Rupp; Martin Witzenrath; Tobias Welte; Mathias W. Pletz

doi:10.1183/13993003.02432-2021

A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany

Christina Bahrs, Miriam Kesselmeier, Martin Kolditz, Santiago Ewig, Gernot Rohde, Grit Barten-Neiner, Jan Rupp, Martin Witzenrath, Tobias Welte, Mathias W. Pletz^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Institut für Medizinische Mikrobiologie

20 Zitate (Scopus)

Abstract

In Germany, the recently approved 20-valent pneumococcal conjugate vaccine had a substantially higher coverage against pneumonia in adults than the 13-valent vaccine, while the coverage gap compared to the 23-valent polysaccharide vaccine was small https://bit.ly/3q4skov

Originalsprache	Englisch
Zeitschrift	European Respiratory Journal
Jahrgang	59
Ausgabenummer	2
ISSN	0903-1936
DOIs	https://doi.org/10.1183/13993003.02432-2021
Publikationsstatus	Veröffentlicht - 01.02.2022

Fördermittel

(CM-COVID). This study was supported by an unrestricted grant from Pfizer. Teva, and research funding from Actelion, Bayer Health Care, Biotest, partly supported by a grant of the Federal Ministry of Education and Research

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

Dokumente

10.1183/13993003.02432-2021

Weitere Links

Link to publication in Scopus

Zitieren

@article{06a1acb384e84b9686a69a0a87b88107,

title = "A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany",

abstract = " In Germany, the recently approved 20-valent pneumococcal conjugate vaccine had a substantially higher coverage against pneumonia in adults than the 13-valent vaccine, while the coverage gap compared to the 23-valent polysaccharide vaccine was small https://bit.ly/3q4skov ",

author = "Christina Bahrs and Miriam Kesselmeier and Martin Kolditz and Santiago Ewig and Gernot Rohde and Grit Barten-Neiner and Jan Rupp and Martin Witzenrath and Tobias Welte and Pletz, \{Mathias W.\}",

note = "Funding Information: (CM-COVID). This study was supported by an unrestricted grant from Pfizer. Funding Information: Teva, and research funding from Actelion, Bayer Health Care, Biotest, Funding Information: partly supported by a grant of the Federal Ministry of Education and Research",

year = "2022",

month = feb,

day = "1",

doi = "10.1183/13993003.02432-2021",

language = "English",

volume = "59",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "2",

}

TY - JOUR

T1 - A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany

AU - Bahrs, Christina

AU - Kesselmeier, Miriam

AU - Kolditz, Martin

AU - Ewig, Santiago

AU - Rohde, Gernot

AU - Barten-Neiner, Grit

AU - Rupp, Jan

AU - Witzenrath, Martin

AU - Welte, Tobias

AU - Pletz, Mathias W.

N1 - Funding Information: (CM-COVID). This study was supported by an unrestricted grant from Pfizer. Funding Information: Teva, and research funding from Actelion, Bayer Health Care, Biotest, Funding Information: partly supported by a grant of the Federal Ministry of Education and Research

PY - 2022/2/1

Y1 - 2022/2/1

N2 - In Germany, the recently approved 20-valent pneumococcal conjugate vaccine had a substantially higher coverage against pneumonia in adults than the 13-valent vaccine, while the coverage gap compared to the 23-valent polysaccharide vaccine was small https://bit.ly/3q4skov

AB - In Germany, the recently approved 20-valent pneumococcal conjugate vaccine had a substantially higher coverage against pneumonia in adults than the 13-valent vaccine, while the coverage gap compared to the 23-valent polysaccharide vaccine was small https://bit.ly/3q4skov

UR - https://www.scopus.com/pages/publications/85124056875

U2 - 10.1183/13993003.02432-2021

DO - 10.1183/13993003.02432-2021

M3 - Journal articles

C2 - 34824055

AN - SCOPUS:85124056875

SN - 0903-1936

VL - 59

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 2

ER -

A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

Dokumente

Weitere Links

Fingerprint

Zitieren